Clinical characteristics and laboratory testing of patient with Sar CoV2 infection
Article Sidebar
Main Article Content
Abstract
Background: Sar CoV2, a novel coronavirus was identified as the cause of respiratory abnormality diseases COVID-19. It has no specific symptoms and the transmission occurs via respiratory droplets or contaminated surfaces. Seroprevalence studies of many diseases have been found to be useful to detect people who were exposed to infection and reveal the burden of the disease.
Objectives: This study aimed to assess the correlation between Clinical findings and laboratory testing of patients with Sar CoV2 infection as derived by RT PCR detection and to investigate serological antibody of IgM, IgG in serum of Covid19 hospitalized patients.
Materials and methods: The study was conducted on 168 patients with positive RT PCR for COVID-19 during June 2021- January 2022 in Khon Kaen Hospital. The nasopharyngeal swabs and blood samples were obtained on the day of admission. Data collection of patient’s clinical symptoms and laboratory testing were recorded for statistical analysis. We performed CBC and anti Sar CoV2 (IgM,IgG) according to standard laboratory methods.
Results: The results indicated that seroprevalence of anti Sar CoV2 in COVID-19 patients was approximately 28% (47/168). The laboratory markers of CBC; as WBC, neutrophil, lymphocyte and platelet demonstrated lower significance. No correlation was observed between Ct of RT PCR with clinical signs and symptoms of COVID-19 patients. In case of RBC, Hemoglobin and Hematocrit, there were also no correlation with clinical characteristics of COVID-19 patients.
Conclusion: The study observed that WBC count and platelet count was significantly lower for some cases. However, awareness of these parameters is required, because of the large heterogeneity in test performance. From serological tests it was observed that anti Sar CoV2 is not suitable diagnosis of the acute phase of infection. Both tests can be used to help RT PCR for diagnosis of Sar CoV2 infection.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance. 2020. Available: http://app.who.int/iris/handle/10665/ 331509[Accessed 11 May 2020].
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel corona virus emerging in /china: Key questions for impact assessment. N Eng J Med. 2020; 382:692-4.
Syangtan G, Bista S, Dawadi P, Rayamajhee B, Shrestha LB, Tuladhar R, Joshi DR. Asymptomatic SAR CoV2 carriers: A systemic review and meta- analysis. Front. Public Health 2020; 8.
Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparable therapeutic efficacy of remdessivir and combination lopinavir, ritonavir and interferon beta against MERS-CoV Nat Commun. 2020; 11(1): 1-14.
Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM,IgA,IgG and neutralization antibodies after infection with SAR-associated coronavirus. Clin. Microbiol. Infect. 2004; 10: 1062-6.
Wang Y, Li J, Li H, Lei P, Shen G, Yang C. Persistence of SARS CoV2 specific antibodies in COVID-19 patients. Int. Immunophamacol. 2021; 90 : 10727. [CrossRef] [PubMed]
Imai K, Tabata S, Ikeda M, Noguchi S, Kitahawa Y, Matuoka M, et al. Clinical evaluation of and immunochromatographic IgM/IgG antibody assay and chest computed tomograpgy for the diagnosis of COVID-19. J. Clinical Virololgy. 2020; 10493; 128: 1-4.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristic of coronavirus disease 2019 in China. N Eng J Med. 2020; 382(18) : 1708-20.
Arentz M, Yim E, Klaff L. et al. Characteristic and outcomes of 21 Critically ill patients with COVID-19 in Washington state. JAMA. 2020; 323(16): 1612-4.
Grasselli G, Pesenti A, Cecconi M. Critical care utilization for COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response [published online March 13,2020] JAMA doi: IO.IOO/jama.2020.403I.
Huang C, Wang X, Li L, Ren J, Zhao YH,Zhang G, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
Grasselli G, Zangrillo A, Zanella A. et al. Baseline characteristics and outcomes of 1591 patients infected with Sar CoV2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020; 323(16): 1574-81.
Guan WJ, Ni ZY, Hu Y, Liang WH, Qu CQ, He JX, et al. Clinical characteristic s of coronavirus disease. 2019 in China. N Engl J Med. 2020; 382(18): 1708-20.
Garcia-Basteiro ALG, Moncunill M, Tortjada M, Vidal C, Guinovart A, Jimenez R, et al. Seroprevalence of antibodies against Sar CoV2 among health care workers in large Spanish reference hospital. Nat.Commun.2020; 11 :3500.
Wu F, Wang A, Liu M, Wang Q, Chen J, Gu C, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med,2020; 180(10) : 1356-62.
Ozcan E, Yavuzer S, Borku BU, Islamoglu MS, Ikitimur H, Unal OF, et al. The relationship between positivity for COVID-19 RT PCR and symptoms, clinical finding and mortality in Turkey. 2020; https://doi.org/10.1080/14737159.2021.1882305.